# NM_001083614.2(EARS2):c.244C>T (p.Arg82Cys)

https://sugi.bio/variant/ears2-p-arg82cys

## Summary

**EARS2 p.Arg82Cys (c.244C>T)** is classified **Uncertain significance** in EARS2 (ClinVar, Multiple submitters, 4 submitters; last evaluated 2025-11-08). AlphaMissense: likely pathogenic (0.9307); Ultra-rare (popmax 0.01%, amr); Associated with leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome.

**At a glance:** Uncertain significance · review: Multiple submitters · rsID rs201848368 · 4 submitters · 1 linked condition · AlphaMissense likely pathogenic · ultra-rare (popmax 0.01%, amr)

## For patients & families {#patients}

This is a change in the EARS2 gene that is currently of uncertain significance — a definitive interpretation has not yet been established, submitted by 4 submitters, and is linked to leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

|  |  |
| --- | --- |
| Typical inheritance (of this condition) | No data available |
| Age of onset (of this condition) | Infancy, Neonatal |
| Diagnostic panels | EARS2 is a diagnostic-grade gene on 13 Genomics England panels |

**Support & next steps:** [Condition overview & support (NIH GARD)](https://rarediseases.info.nih.gov/diseases/0013381/index) · [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [EARS2](https://sugi.bio/atlas/gene/EARS2/) |
| Protein change (HGVS p.) | p.Arg82Cys |
| Coding change (HGVS c.) | c.244C>T |
| MANE Select transcript | [NM_001083614](https://www.ncbi.nlm.nih.gov/nuccore/NM_001083614) |
| dbSNP | [rs201848368](https://www.ncbi.nlm.nih.gov/snp/rs201848368/) |
| Variant type | single nucleotide variant |
| Location | chr16:23552200-23552200 (GRCh38) |
| ClinVar | [VCV1384647](https://www.ncbi.nlm.nih.gov/clinvar/variation/1384647/) |

**All HGVS expressions:** `NC_000016.10:g.23552200G>A`, `NC_000016.9:g.23563521G>A`, `NG_027752.2:g.10176C>T`, `NM_001083614.1:c.244C>T`, `NM_001083614.2:c.244C>T`, `NM_001308211.1:c.244C>T`, `NR_003501.2:n.251C>T`

## Computational & population evidence {#evidence}

**Concordance:** ClinVar classifies this **uncertain**; the computational predictors unanimously lean **damaging** — a triage signal, not a reclassification.

- AlphaMissense **likely pathogenic** (0.9307)
- REVEL 0.548 (indeterminate)
- SaProt LLR -15.102 (damaging) — agrees with AlphaMissense
- → **In-silico consensus:** AlphaMissense and SaProt both call this damaging; REVEL makes no call
- Conservation: phyloP 11.674, GERP 1.71, phastCons 1 — highly conserved (agrees)
- CADD: **PHRED 33.0**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- Regional missense constraint: **o/e 1.15** across the covering region of the MANE Select transcript (23,535,236–23,557,343), spanning 22,107 bp. Chi-square p 0.014. Describes the region, not this allele; gnomAD v4.1.1's own constrained determination. *Descriptive; no ACMG code applied.*
- SpliceAI: **not assessed** — no allele at this position is in our SpliceAI release, either because it lies outside the scored MANE transcript scope or because every allele is below Δ0.2. We cannot tell which, so this claims neither; absence is not evidence against a splicing effect.
- Population frequency (gnomAD v4.1): grpmax **0.01%** (amr) · FAF95 0.00428% · FAF99 0.00295% · 6/59,998 in the highest group · 43/1,614,028 alleles overall — ultra-rare (popmax 0.01%, amr).

| Ancestry group | Allele frequency | 1 in |
| --- | --- | --- |
| Ashkenazi Jewish (not grpmax-eligible) | 0.0878% | 1,139 |
| Admixed American (grpmax) | 0.01% | 10,000 |
| Remaining individuals (not grpmax-eligible) | 0.0016% | 62,484 |
| South Asian | 0.0011% | 91,082 |
| European (non-Finnish) | 0.000763% | 131,115 |

Ashkenazi Jewish shows a higher raw frequency than the grpmax group. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and "Remaining individuals" — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**EARS2** population constraint: LOEUF 1.138, pLI 7.0535e-14, missense-Z 0.080959; ClinGen dosage — haploinsufficiency 30, triplosensitivity 0 (0–3 scale). *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

Curated gene–disease validity (ClinGen):

- **Leigh syndrome** — Definitive (AR)
- **mitochondrial disease** — Definitive (AR)

## Protein context {#protein}


AlphaFold model confidence (whole protein): pLDDT 89.84, 79% of residues very-high.

## What this gene does {#gene-function}

*Describes the biological roles of EARS2 (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*

**How this variant is thought to act:** EARS2's established molecular role includes glutamate-tRNA ligase activity.


### Pathways affected {#pathways}

EARS2 participates in **1 Reactome pathway** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| [Mitochondrial tRNA aminoacylation](https://reactome.org/content/detail/R-HSA-379726) | electronic |

### Molecular function & processes (GO — experimentally supported) {#go}

**Molecular function:** glutamate-tRNA ligase activity, glutamate-tRNA(Gln) ligase activity.

**Biological process:** glutamyl-tRNA aminoacylation, tRNA aminoacylation for mitochondrial protein translation.

## Clinical significance {#significance}

**Uncertain significance** — review status Multiple submitters *(criteria provided, multiple submitters, no conflicts)*, last evaluated 2025-11-08.

**Submitter consensus:** unanimous (4/4 Uncertain significance).

**Submission history:** 4 submissions (2022–2025); classifications have been stable.

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| 3billion | Uncertain significance | criteria provided, single submitter | clinical testing | 2023-02-23 |
| Ambry Genetics | Uncertain significance | criteria provided, single submitter | clinical testing | 2025-11-08 |
| Labcorp Genetics (formerly Invitae), Labcorp | Uncertain significance | criteria provided, single submitter | clinical testing | 2022-09-07 |
| Blueprint Genetics | Uncertain significance | criteria provided, single submitter | clinical testing | 2023-11-06 |

## Associated conditions {#conditions}

[leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome](https://sugi.bio/atlas/disease/leukoencephalopathy-thalamus-and-brainstem-anomalies-high-lactate-syndrome/).

**Reported phenotype names (ClinVar):** Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome, not provided, Inborn genetic diseases, LEUKOENCEPHALOPATHY WITH THALAMUS AND BRAINSTEM INVOLVEMENT AND HIGH LACTATE, Combined oxidative phosphorylation deficiency 12, none provided.

## Similar variants {#similar}

Related EARS2 variant pages (same residue, condition, or type): [EARS2 p.Arg82=](/variant/ears2-p-arg82), [EARS2 p.Arg82His](/variant/ears2-p-arg82his), [EARS2 p.Arg107His](/variant/ears2-p-arg107his), [EARS2 p.Arg108Trp](/variant/ears2-p-arg108trp), [EARS2 p.Cys167Tyr](/variant/ears2-p-cys167tyr), [EARS2 p.Met1Val](/variant/ears2-p-met1val), [EARS2 p.Ser143Ter](/variant/ears2-p-ser143ter), [EARS2 p.Arg162Trp](/variant/ears2-p-arg162trp).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-11); gnomAD v4.1 (Broad Institute, built 2026-10-06); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-07-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 1384647). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*